Competition

The COVID-19 pandemic has highlighted the necessity of finding health solutions in an unprecedentedly short length of time. However, the first treatments, tests and vaccines will only offer partial solutions. Competing follow-on technologies will offer better or complementary health benefits. It is essential that health systems do not put all of their eggs in one basket.

OHE Lunchtime Seminar with Pedro Pita Barros on ‘Incentives for R&D, Competition and Intertemporal Effects of Payment Rules for Cures’. To be held on 6 June 2019 from 12 p.m. to 2 p.m.

Current payment and pricing rules for pharmaceutical products do not account for...

OHE Lunchtime Seminar with Dr. Aslam Anis, The University of British Columbia. The seminar will discuss the impact of the pan-Canadian Pharmaceutical Alliance “tiered pricing” framework (a flexible 'price-cap' regulation) on generic entry, the resulting drug expenditure levels from a drug plans’ perspective and the implications of price-capping policies on drug shortages.

OHE Lunchtime Seminar with Dr. Aslam Anis, The University of British Columbia. The seminar will discuss the impact of the pan-Canadian Pharmaceutical Alliance “tiered pricing” framework (a flexible 'price-cap' regulation) on generic entry, the resulting drug expenditure levels from a drug plans’ perspective and the implications of price-capping policies on drug shortages.

A new OHE Briefing by Martin Chalkley (University of York) and Jon Sussex (RAND Europe) provides a view of the NHS ownership debate through the lens of economics.

To what extent can R&D incentives, competition and other factors facilitate access to highly valuable and costly pharmaceutical innovations?

A new OHE Seminar Briefing by Chris Mullin, Chief Economist at the Department of Health, examines growth in expenditure on NHS agency staffing.

OHE Lunchtime Seminar with Professor Martin Chalkley and Jon Sussex: Providing Health Care to NHS Patients: How Much Does Ownership Matter?

Drug prices in the US might overstate pharmaceuticals' long-run cost up to 75%. True long-term costs then must be considered by market access and policy decisions.

Professor David Grabowski from Harvard University will lead an OHE Lunchtime Seminar on 19 April 2017 on the topic of interventions that encourage high-value nursing home care: lessons for the UK.

Pages

Subscribe to RSS - Competition